AstraZeneca PLC Announces Agreement with Cheplapharm for rights to Atacand in 28 European countries completed
1 October 2018 07:00 BST AstraZeneca has completed an agreement with Cheplapharm Arzneimittel GmbH (Cheplapharm) for the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe. Under the terms of the agreement, AstraZeneca has received a payment of $200 million from Cheplapharm. A time-bound payment of $10 million as well as sales-contingent milestones will also be payable. The present value of the upfront and time-bound payments will be reported as Other Operating Income in the company'